Davis Polk advised the sole book-running manager and representative of the several underwriters in connection with a $45 million SEC-registered common stock and pre-funded warrants offering by IVERIC bio. IVERIC’s common stock is listed on the Nasdaq Global Select Market under the symbol “ISEE.”

Based in New York and New Jersey, IVERIC is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. IVERIC is currently developing both therapeutic candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Joseph S. Payne and Johnathan M. Nixon. Partner John M. Brandow provided equity derivatives advice. The tax team included counsel Ethan R. Goldman and associate Rachel Lerner. Associate Jay Frankel provided intellectual property and technology advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.